Uncovering Mechanisms of Immune-Based Therapy in Cancer and Autoimmunity
Organizer(s): Daniel J. Cua, E. John Wherry and Carla V. RothlinDate: February 18 - 22, 2019
Location: Beaver Run Resort, Breckenridge, CO, USA
Significant progress has been made in the field of immunology over the past two decades. Therapeutic agents such as anti-TNF, anti-CD20, anti-CTLA4, and more recently, anti-PD1 have benefited countless patients. This is a unique time for immunologists and clinical scientists to learn from the sheer number of clinical trials assessing immune targets for treatment of cancer and autoimmunity. Currently, there are more than 500 clinical studies testing combinations of checkpoint inhibitors with other pathway antagonists, which will begin to uncover the “immune mechanisms” driving the disease process. This is highlighted by the observation that more than 10-20% of patients treated with anti-PD1 and/or CTLA4 later suffer from autoimmunity (e.g., anti-PD1 treatment is linked to Type 1 diabetes and anti-CTLA-4 treatment is linked to inflammatory bowel disease). Response rate to cancer treatment is greater in patients with autoimmune predisposition; therefore the autoimmune side effect is in part associated with patient genetics. The meeting topics will include discussions of combination immunotherapies, the genetics of patient response, and strategies to reprogram adaptive and innate immunity, which are key to harnessing the immune system to fight cancer and autoimmune diseases. The meeting will end with a special closing lecture on the future of immunotherapy.
Scholarship Deadline: October 23 2018
Discounted Abstract Deadline: October 23 2018
Abstract Deadline: November 15 2018
Discounted Registration Deadline: December 18 2018
We gratefully acknowledge additional support from these exhibitors at this conference:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Dynavax Technologies Corporation
Merck & Co., Inc.
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1 R13 CA232437-01
Funding for this conference was made possible (in part) by 1 R13 CA232437-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.